Charles River Laboratories International (CRL) Liabilities and Shareholders Equity (2009 - 2026)

Charles River Laboratories International has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $7.5 billion in Q2 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed 0.38% year-over-year to $7.5 billion in Q2 2026; TTM through Jun 2026 was $29.9 billion, a 2.49% decrease from a year earlier, with the FY2025 full-year figure at $7.1 billion, down 5.22% from the prior year.
• Liabilities and Shareholders Equity was $7.5 billion for Q2 2026 at Charles River Laboratories International, down from $7.7 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $8.2 billion in Q4 2023, with the low at $7.1 billion in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $7.6 billion, with a median of $7.6 billion recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity climbed 21.8% in 2022, then dropped 8.13% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $7.6 billion in 2022, then rose by 7.79% to $8.2 billion in 2023, then slipped by 8.13% to $7.5 billion in 2024, then dropped by 5.22% to $7.1 billion in 2025, then grew by 5.56% to $7.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $7.5 billion (Q2 2026), $7.7 billion (Q1 2026), and $7.1 billion (Q4 2025), per Business Quant data.